SCHEMBL6283431

SCHEMBL6283431

[CH2]c1cn(C(=O)OCC)c2ccccc12

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.53
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
ALDH1A1 P00352 5/20 0.46
KDM4E B2RXH2 4/20 0.46
MAPT P10636 2/20 0.46
LMNA P02545 2/20 0.44
CREBBP Q92793 1/20 0.44
ELANE P08246 2/20 0.43
POLB P06746 2/20 0.43
NTRK1 P04629 1/20 0.43
BCHE P06276 1/20 0.43
HPGD P15428 1/20 0.43
TSHR P16473 1/20 0.43
HSD17B10 Q99714 1/20 0.43
SAE1 Q9UBE0 1/20 0.43
UBA2 Q9UBT2 1/20 0.43
RAB9A P51151 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8089256 0.89 MEN1 (0.44) L3MBTL1MEN1KMT2AALDH1A1KDM4E
SCHEMBL8083500 0.87 BCHE (0.49) L3MBTL1MEN1KMT2AALDH1A1KDM4E
SCHEMBL2114760 0.85 L3MBTL1 (0.54) L3MBTL1MEN1KMT2AALDH1A1KDM4E
SCHEMBL8083506 0.85 P2RX4 (0.46) L3MBTL1MEN1KMT2AALDH1A1KDM4E
SCHEMBL8076272 0.83 KMT2A (0.67) L3MBTL1MEN1KMT2AALDH1A1KDM4E
SCHEMBL8530895 0.83 KDM1A (0.49) L3MBTL1MEN1KMT2AALDH1A1RAB9A
SCHEMBL28568208 0.83 ALDH1A1 (0.51) L3MBTL1MEN1KMT2AALDH1A1KDM4E
SCHEMBL9164757 0.83 L3MBTL1 (0.60) L3MBTL1MEN1KMT2AALDH1A1KDM4E
SCHEMBL2544694 0.83 L3MBTL1 (0.52) L3MBTL1MEN1KMT2AALDH1A1KDM4E
SCHEMBL2457012 0.81 KMT2A (0.64) L3MBTL1MEN1KMT2AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1486207-A2 Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same SHIONOGI & CO., LTD. (JP) 2004-12-15 EP claimed
US-20030225043-A1 Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same SHIONOGI & CO., LTD. 2003-12-04 US claimed
US-20030139379-A1 Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same SHIONOGI & CO., LTD. 2003-07-24 US claimed
EP-0950656-A1 SULFONATED AMINO ACID DERIVATIVES AND METALLOPROTEINASE INHIBITORS CONTAINING THE SAME SHIONOGI & CO., LTD. (JP) 1999-10-20 EP claimed
CN-1214041-A Sulfonated amino acid derivatives and metalloprotease inhibitors containing the same SHINOGI CO (JP) 1999-04-14 CN claimed
CN-100413859-C Sulfonated amino acid derivatives and metalloprotease inhibitors containing the same SHINOGI CO (JP) 2008-08-27 CN disclosed
US-6919375-B1 Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same SHIONOGI & CO., LTD. (JP) 2005-07-19 US disclosed
US-6881727-B2 Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same SHIONOGI & CO., LTD. (JP) 2005-04-19 US disclosed
US-6838483-B2 Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same SHIONOGI & CO., LTD. (JP) 2005-01-04 US disclosed
EP-1486207-A2 Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same SHIONOGI & CO., LTD. (JP) 2004-12-15 EP disclosed
US-20030225043-A1 Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same SHIONOGI & CO., LTD. 2003-12-04 US disclosed
US-20030139379-A1 Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same SHIONOGI & CO., LTD. 2003-07-24 US disclosed
EP-0460679-B1 Endothelin antagonistic peptide derivatives BANYU PHARMA CO LTD (JP) 1998-10-28 EP disclosed
US-5691315-A CARDIOVASCULAR DISORDERS; VASODILATOR; BRONCHODILATOR BANYU PHARMACEUTICAL CO., LTD. (JP) 1997-11-25 US disclosed
US-5614498-A OLIGOPEPTIDES, BRONCHDILATORS BANYU PHARMACEUTICAL CO., LTD. (JP) 1997-03-25 US disclosed
US-5496928-A Endothelin antagonistic substance BANYU PHARMACEUTICAL CO., LTD. (JP) 1996-03-05 US disclosed
US-5470833-A Vasodilators, bronchodilators BANYU PHARMACEUTICAL CO., LTD. (JP) 1995-11-28 US disclosed
US-5444152-A Vasolidator or bronchodilator BANYU PHARMACEUTICAL CO., LTD. (JP) 1995-08-22 US disclosed
EP-0555537-A2 Endothelin antagonistic substance BANYU PHARMACEUTICAL CO., LTD. (JP) 1993-08-18 EP disclosed
EP-0460679-A2 Endothelin antagonistic peptide derivatives Banyu Pharmaceutical Co., Ltd. (JP) 1991-12-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030139379-A1 Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same MMP9, MMP2, MMP1 L3MBTL1 4563/4885MEN1 1773/4885KMT2A 1540/4885
US-20030225043-A1 Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same MMP9, MMP2, MMP1 L3MBTL1 4563/4885MEN1 1773/4885KMT2A 1540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.